Ozempic has the edge on Rybelsus for better efficacy in glucose control and weight loss
Each medication affects glycemic control through slightly different mechanisms
Such efforts will be crucial for unlocking sesames full potential as a functional food ingredient and as a contributor to sustainable food systems
Available data are insufficient to inform recommendations to mitigate the risk of pulmonary aspiration during general anesthesia or deep sedation in patients taking ZEPBOUND, including whether modifying preoperative fasting recommendations or temporarily discontinuing ZEPBOUND could reduce the incidence of retained gastric contents
[Ref] Gastrointestinal Very common (10% or more): Diarrhea (57.9%), abdominal pain (43.9%), nausea (29.8%), flatulence (25.3%), constipation (18.8%), abdominal pain upper (10.5%), abdominal discomfort, loose stools Common (1% to 10%): Fat malabsorption, vomiting, dyspepsia, steatorrhea, discoloration of feces, tenesmus, abdominal distension Uncommon (0.1% to 1%): GI bleeding, hemorrhoids, appendicitis, gastric/peptic ulcer Frequency not reported : Pancreatitis, vomiting, abnormal stools, severe epigastric pain, abdominal tenderness and guarding Postmarketing reports : Intestinal obstruction [Ref] Cardiovascular Very common (10% or more): Bradycardia (25%), hypertension (12.6%), conduction abnormalities (10%) Common (1% to 10%): Arrhythmias, flushing Uncommon (0.1% to 1%): Chest pain, shortness of breath, thrombophlebitis, ischemia, congestive heart failure, palpitations, orthostatic blood pressure decrease, tachycardia [Ref] Hepatic Very common (10% or more): Gallstones (27%), sludge without stones (24%), cholelithiasis (38.2%), biliary duct dilatation (12%) Common (1% to 10%): Transaminase increased Uncommon (0.1% to 1%): Hepatitis, jaundice, increase in liver enzymes, gallbladder polyp Rare (less than 0.1%): Acute pancreatitis Frequency not reported : Acute cholecystitis, ascending cholangitis, biliary obstruction, cholestatic hepatitis, pancreatitis [Ref] Nervous system Very common (10% or more): Headache (30%), dizziness (20%) Uncommon (0.1% to 1%): Syncope, tremor, seizure, vertigo, Bell's palsy, pituitary apoplexy, amnesia, neuritis [Ref] Metabolic Very common (10% or more): Hyperglycemia (16%) Common (1% to 10%): Hypoglycemia, edema, anorexia Uncommon (0.1% to 1%): Weight loss, dehydration Frequency not reported : Depressed vitamin B12 levels, abnormal Schilling's test [Ref] Hematologic Very common (10% or more): Anemia (15.3%) Uncommon (0.1% to 1%): Iron deficiency Postmarketing reports : Thrombocytopenia [Ref] Endocrine Very common (10% or more): Biochemical hypothyroidism (12%) Common (1% to 10%): Goiter, thyroid dysfunction (e.g
Your PlexusDx provider will monitor your tolerance and results throughout this schedule, adjusting timing if needed based on your unique physiology
